AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03912324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Empirical PV isolation group
Description: 1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~4. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~5. Evaluate time to complete isolation after additional ablation~6. Evaluation of Procedure time, Ablation time, and perfusion saline dose~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study NCT05288920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
Description: Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
Study NCT05538377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Vibration
Description: This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
Study NCT05538377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
Study NCT05667610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immune-supportive diet
Description: The intervention includes a immune-supportive diet over a period of 4 months
Study NCT05667610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immune-supportive diet
Description: The intervention includes a immune-supportive diet over a period of 4 months
Study NCT06436222 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HVNI
Description: Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.
Study NCT06159244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool withdrawal
Description: stool withdrawal at day 0 and day 7
Study NCT06159244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stool withdrawal
Description: stool withdrawal at day 0 and day 7
Study NCT04424394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DualStim Therapy
Description: 6 DualStim Therapies over a period of 7 weeks.
Study NCT05793372 — intervention group
Intervention type: OTHER
Intervention: Retrospective study of clinical features
Description: Retrospective study of clinical features
Study NCT06190418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loaded sit to stand strengthening exercise
Description: This Group will be given with the wieghted vest equal to that of 1RM for each child and Sit-to-Stand Strengthening Excerise will be given 3 times per week for 6 weeks
Study NCT06190418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unloaded sit to stand strengthening exercise
Description: This Group will be given with the Sit-to-Stand Strengthening Excerise without any external load for 3 times per week for 6 weeks
Study NCT06401252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: • The mindful mediators are asked to act as neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each 19 stimuli. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting)
Study NCT05546749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RelieVRx
Description: The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
Study NCT05546749 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
Study NCT04869189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JJVC Marketed Contact Lens
Description: Acuvue Oasys® 1-Day
Study NCT05242809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based PFMT group
Description: The intervention group receives PFMT supervision in groups of about 6-8 women
Study NCT04424394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DualStim Therapy
Description: 6 DualStim Therapies over a period of 7 weeks.
Study NCT04424394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord-derived Wharton's Jelly
Description: 2 intracavernosal injections over a period of 7 weeks.
Study NCT04424394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 2 intracavernosal injections over a period of 7 weeks.
Study NCT04820114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive wrist exercises
Description: Exercises for recognition of writs position and thumb force sense.
Study NCT04820114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wrist exercises
Description: Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
Study NCT04820114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist exercises
Description: Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
Study NCT05302869 — intervention group
Intervention type: OTHER
Intervention: None intervention
Description: None intervention
Study NCT06121076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDM-EBP training
Description: A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
Study NCT06121076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SDM-EBP training
Description: A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
Study NCT06264466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POEM with Speedboat Ultraslim
Description: POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
Study NCT04930120 — intervention group
Intervention type: OTHER
Intervention: Inter ICU long distance patient transfer
Description: Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
Study NCT04293224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA Mediterranean diet pattern, energy balance
Description: Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
Study NCT04293224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA Mediterranean diet pattern, negative energy balance
Description: Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
Study NCT04293224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAD diet pattern, negative energy balance
Description: Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
Study NCT05288920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transforaminal injection of Steroids alone
Description: Transforaminal injection of Steroids alone
Study NCT06404658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block
Description: patients who receive Genicular nerve block with spinal anathesia .
Study NCT06299020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intermittent fasting
Description: fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.
Study NCT05066750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful breathing
Description: Participants watch a 10 minute mindful breathing video
Study NCT05066750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control video
Description: Participants watch a 10 minute control video
Study NCT06113809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab
Study NCT06113809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)
Study NCT05851495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapist-led groups, home-based follow up groups
Description: The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises
Study NCT05819502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane line of injectables
Description: Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
Study NCT05622656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.0005%
Study NCT05622656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Solution
Study NCT05642793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proactive Anti-VEGF (conbercept) use
Description: preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
Study NCT05642793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: passive Anti-VEGF (conbercept) use
Description: No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
Study NCT06190717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchoMark/EchoSure
Description: Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.
Study NCT06190717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
Study NCT05486598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 tablets
Description: Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach.
Study NCT06521619 — intervention group
Intervention type: PROCEDURE
Intervention: Femoral and sciatic nerve blocks
Description: Patients receiving Adductor canal block and infiltration of posterior capsule of knee
Study NCT05824559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-344
Description: ME-344 will be administered intravenously (IV)
Study NCT05824559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously (IV)
Study NCT06614270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK cells
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) on day -5, -4, and -3. Doses of 2×10\^6/kg, 3×10\^6/kg, 4×10\^6/kg anti-CD19 CAR-NK cells will be infused in each group on Day 0, 7, and 14 using the \&#34;3 + 3\&#34; dose-escalation strategy.
Study NCT05585346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MLS laser
Description: Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
Study NCT05585346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLS laser
Description: Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
Study NCT05585346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral vitamin B1
Description: Oral vitamin B1 10mg, times/day
Study NCT05585346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral vitamin B1
Description: Oral vitamin B1 10mg, times/day
Study NCT06698848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamin
Description: Participants in this study will have been diagnosed with major depressive episode (MDE) and have not received any psychiatric treatment for at least 2 weeks (5 weeks if on fluoxetine).Patients will receive intravenous ketamine as the only study drug treatment for the 2 weeks of the study. Magnetic Resonance Imaging (MRI) will be used to measure effects of ketamine on brain structure, function and chemistry, in addition to a soft-nasal brushing procedure to obtain olfactory sensory neurons which will provide the ability to profile in vivo how neurons may react to KET treatment in depressed patients.
Study NCT05082766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enhanced DefenAge 8-in-1 BioSerum
Description: DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
Study NCT05232292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrix Quadri
Description: vaccination by Ultrix Quadri against flu
Study NCT05367050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucid Lane Therapy Program
Description: This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
Study NCT05367050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Preparedness Course
Description: This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
Study NCT06443411 — intervention group
Intervention type: OTHER
Intervention: Monitoring of cerebral hemodynamics
Description: A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.
Study NCT06120192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano
Description: Receives the piano training
Study NCT04443868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Releasing Drug
Description: Nasal Spray + Nasal Irrigation
Study NCT04443868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitric Oxide-Releasing Drug
Description: Nasal Spray + Nasal Irrigation
Study NCT04915872 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling (T0, inclusion)
Description: Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)
Study NCT04915872 — intervention group
Intervention type: PROCEDURE
Intervention: other samplings (T1)
Description: - T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)
Study NCT05318170 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic ultra-radical lymph node debulking
Description: Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
Study NCT04524390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: A small molecule inhibitor of the ileal bile acid transporter (IBAT)
Study NCT04524390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to maralixibat except for the active drug substance
Study NCT05230303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Description: Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.